News | May 01, 2012

FDA Panel Recommends Approval of Cameron Health's Subcutaneous S-ICD System


May 1, 2012 — Cameron Health Inc. announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel voted 7-1 that sufficient data exists demonstrating the efficacy and safety of the S-ICD (subcutaneous-implantable cardioverter defibrillator) system for the treatment of sudden cardiac arrest (SCA).

"We are pleased with the panel's strong recommendation for approval of the S-ICD system, the world's first and only completely subcutaneous ICD for the treatment of sudden cardiac arrest," said Kevin Hykes, president and CEO of Cameron Health. "This represents another important step on the path toward FDA approval of the S-ICD system and its availability to physicians and their patients at risk for sudden cardiac arrest."

Cameron Health submitted a premarket approval application (PMA) in December 2011 based on data from a 330-patient pivotal investigational device exemption (IDE) clinical study that evaluated the safety and efficacy of the S-ICD system in patients at risk of SCA.

"The S-ICD system is a breakthrough technology that holds promise as a new alternative for treating patients at risk for sudden cardiac arrest," said Michael R. Gold, professor of medicine and chief of cardiology at the Medical University of South Carolina. "The S-ICD system provides the same defibrillation protection as conventional ICDs, but without the serious complications associated with leads that reside in the heart and blood vessels."

On March 8, 2012, Boston Scientific Corp. announced that it would exercise its option to acquire Cameron Health. Closing of the transaction is subject to customary conditions, including relevant antitrust clearance, and is expected to occur in the second or third quarter of 2012.

For more information: www.cameronhealth.com


Related Content

News | Implantable Cardioverter Defibrillator (ICD)

August 29, 2022 — Medtronic plc announced that its investigational EV ICD System – a first-of-its-kind defibrillator ...

Home August 29, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 18, 2022 — A first-in-human multicenter trial involving Mayo Clinic used a new ablation technique for patients ...

Home August 18, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)

July 21, 2022 — The global automated external defibrillators market size was valued at USD 717 million in 2021. It is ...

Home July 22, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)

June 10, 2022 — Setting a lower price to enter a competitive market with established brand leaders is a common ...

Home June 10, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)
May 2, 2022 – High-risk patients who need defibrillators to prevent cardiac arrest can experience fewer complications ...
Home May 02, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)
February 14, 2022 — Philips, a global leader in health technology, is supporting the American Heart Association’s multi ...
Home February 14, 2022
Home
Feature | Implantable Cardioverter Defibrillator (ICD) | By Dave Fornell, Editor

February 2, 2020 — The U.S. Food and Drug Administration (FDA) has identified a recent recall of the Boston Scientific ...

Home February 02, 2021
Home
News | Implantable Cardioverter Defibrillator (ICD)

January 8, 2020 — A new study published this week in HeartRhythm, the journal of the Heart Rhythm Society (HRS), found ...

Home January 08, 2021
Home
News | Implantable Cardioverter Defibrillator (ICD)

May 8, 2020 — Final results from the UNTOUCHED study of the Emblem Subcutaneous Implantable Defibrillator (S-ICD) System ...

Home May 08, 2020
Home
Subscribe Now